Skip to content

Clinical Trial §23b MPG with hysan Salinspray in an ENT setting

Clinical Trial §23b MPG with hysan Salinspray in an ENT setting - HYSAL-2016

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00010825
Enrollment
150
Registered
2016-07-13
Start date
2016-06-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diseases of nose and paranasal sinuses J01 J00

Interventions

Group 1: Patients suffering from rhinitis/ sinusitis use the nasal spray hysan Salinspray during the treatment period
1-2 puffs several times per day into each nostril

Sponsors

URSAPHARM Arzneimittel GmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to No maximum

Inclusion criteria

Inclusion criteria: - Adults and children > 1 year - indication for Treatment with hysan Salinspray - doctor's decision to prescribe hysan Salinspray is independent from decistion to include the patient into the study

Exclusion criteria

Exclusion criteria: Due to the non-interventional character of the study, no exclusion criteria are predefined. Contraindications and interactions as described in the package leaflet must be considered.

Design outcomes

Primary

MeasureTime frame
Aims of the study (documentation in Case Report Form at beginning and end of the Treatment): Efficacy: Change in symptoms under Treatment: - nasal obstruction - sneezing attacks - runny nose - post-nasal discharge - thick nasal discharge - desire to clear one's throat/ dry throat - redness of the nasal mucosa - edema of the nasal mucosa - reduction of smell - reduction of taste - impairment of sleep - Impairment of food intake/ appetite Safety: - incidence of adverse reactions under treatment - judgement on tolerability of the treatment

Countries

Germany

Contacts

Public ContactPeter Meiser

URSAPHARM Arzneimittel GmbH

info@ursapharm.de06805-9292-0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 22, 2026